Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Paliwal, Amit
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension	Active, not recruiting	3	1083	Europe, Canada, US, RoW	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	12/24	02/25
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension	Enrolling by invitation	3	1400	Europe, Canada, US, RoW	lorundrostat, Placebo	Mineralys Therapeutics Inc.	Hypertension	12/25	12/26
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec	Recruiting	2	230	US	HDV-Lispro, HDV-L, Lispro, LIS	Diasome Pharmaceuticlas, Inc.	Diabetes Mellitus, Type 1	06/25	12/25
Kwon, Yebin
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec	Recruiting	2	230	US	HDV-Lispro, HDV-L, Lispro, LIS	Diasome Pharmaceuticlas, Inc.	Diabetes Mellitus, Type 1	06/25	12/25
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder	Recruiting	2	300	US	INDV-2000, Placebo	Indivior Inc.	Opioid Use Disorder	08/25	09/25